Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Crohn’s Disease Market Report Overview

The Crohn’s disease market size across the 8MM was $9.5 billion in 2022. The market will achieve a CAGR of more than 4% during 2022-2032 because of the approval and launch of 15 pipeline, generic, and biosimilar therapies.

Crohn’s Disease Market Outlook, 2022-2032 ($ Billion)

Crohn’s Disease Market Outlook, 2022-2032 ($ Billion)

Buy the Full Report to Know More About the Crohn’s Disease Market Forecast

Download a Free Report Sample

The Crohn’s disease market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.

Market Size (2022) $9.5 billion
CAGR (2022-2032) >4%
Forecast Period 2023-2032
Key Countries ·       US

·       France

·       Germany

·       Italy

·       Spain

·       UK

·       Japan

·       Canada

Leading Players ·       AbbVie Inc.

·       Janssen

·       Takeda Pharmaceutical Co Ltd

·       Bristol Myers Squibb

·       Ventyx Biosciences

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Crohn’s Disease Market Dynamics

The emergence of several biosimilar and generic drugs entering the US market will hamper the market growth during the forecast period. However, updated recommendations for the rapid incorporation of newer therapies by healthcare providers will drive the CD market growth in the coming years.

Crohn’s Disease Market Analysis by Treatment

  • Patients with CD are usually diagnosed before the age of 20 years. Individuals presenting with symptoms are typically diagnosed by gastroenterologists, based on a combination of their medical history and endoscopic, radiographic among others.
  • The goal of CD treatment has evolved over the last decade from merely offering symptomatic relief to inducing and maintaining disease remission.
  • Corticosteroids, particularly budesonide-based products, are the treatment of choice for mild to moderate CD due to their low systemic bioavailability. Regardless of disease severity, corticosteroids are used to treat CD patients because they are effective in inducing disease remission.

Buy Full Report for More Insights into the Crohn’s Disease Market Treatment

Download a Free Report Sample

Crohn’s Disease Market Segmentation by Countries

Italy has low drug prices and a small patient population making it the smallest CD market in the 8MM.

A few of the key countries in the CD market are the US, France, Germany, Italy, Spain, the UK, Japan, and Canada. The US had the highest share of the 8MM in 2022 and is anticipated to continue doing so during the forecast period. This can be attributed to the country’s large prevalent CD population as well as the higher drug prices relative to the other major markets.

Crohn’s Disease Market Analysis by Countries, 2022 (%)

Crohn’s Disease Market Analysis by Countries, 2022 (%)

Buy Full Report for More Country Insights into the Crohn’s Disease Market

Download A Free Report Sample

Crohn’s Disease Market - Competitive Landscape

AbbVie Inc. was the market leader of the players associated with CD in 2022.

The current Crohn’s disease market is fairly competitive and is centered around patients suffering from the more severe end of the spectrum of the disease. Some of the major players in the Crohn’s disease market are:

  • AbbVie Inc.
  • Janssen
  • Takeda Pharmaceutical Co Ltd
  • Bristol Myers Squibb
  • Ventyx Biosciences

Crohn’s Disease Market Analysis by Companies, 2022

Crohn’s Disease Market Analysis by Companies, 2022

Buy the Full Report to Know More about Companies in the Crohn’s Disease Market

Download A Free Report Sample

Crohn’s Disease Market – Latest Development

The development of novel MOAs will lower the chances of treatment non-response dramatically. Anti-IL-23 biologics, such as Janssen’s pipeline Tremfya (guselkumab) and AbbVie’s recently approved Skyrizi (risankizumab), demonstrate great promise due to their good efficacy in both anti-TNF-naïve and anti-TNF-experienced patients, while potentially providing safer therapy than Stelara, which targets both IL-23 and IL-12, especially in older patients who are at increased risk for infection or had recent malignancy.

Segments Covered in the Report

Crohn’s Disease Country Outlook (Value, $ Billion, 2022-2032)

  • US
  • France
  • Germany
  • Italy
  • Spain
  • The UK
  • Japan
  • Canada

Scope

The report provides:

  • Overview of CD including epidemiology, disease etiology, and management.​
  • Topline CD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.​
  • Key topics including the assessment of marketed and pipeline therapies, unmet needs, current and future players, and market outlook for the US, 5EU, Japan, and Canada over the 10-year forecast period.​
  • Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.​
  • Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.​
  • Develop business strategies by understanding the trends shaping and driving the global CD therapeutics market.​
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CD market in the future.​
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.​
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.​
  • Track drug sales in the global CD therapeutics market from 2022-2032.​
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.​

AbbVie​
Bristol Myers Squibb​
Janssen​
Lilly​
Merck​
Pfizer​
Takeda​
Telavant​
Teva Pharmaceuticals​
Ventyx Biosciences​

Table of Contents

About GlobalData

1 Crohn’s Disease: Executive Summary

1.1 Steady growth is expected for the CD market from 2022-32

1.2 Novel MOAs will provide market shifts throughout the forecast period

1.3 Lack of tools to properly treat patients with CD is a clear unmet need within the market

1.4 Pipeline Drugs

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 CD Classification

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 8MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed incident cases of CD

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of CD

4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of CD by severity, diagnosed prevalent cases of fistulizing CD by severity, and diagnosed prevalent cases of CD in remission by severity

4.5 Epidemiological forecast for Crohn’s disease (2022–32)

4.5.1 Diagnosed incident cases of CD

4.5.2 Age-specific diagnosed incident cases of CD

4.5.3 Sex-specific diagnosed incident cases of CD

4.5.4 Diagnosed prevalent cases of CD

4.5.5 Age-specific diagnosed prevalent cases of CD

4.5.6 Sex-specific diagnosed prevalent cases of CD

4.5.7 Diagnosed prevalent cases of CD by severity

4.5.8 Diagnosed prevalent cases of fistulizing CD by severity

4.5.9 Diagnosed prevalent cases of CD in remission by severity

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improved Drug Efficacy, Clinical Response, and Sustained Remission

7.3 Biomarkers to Predict Responsiveness to Therapy and Prognosis

7.4 Improved Medical Management of Perianal Fistulas

7.5 Clinical Data to Determine the Most Efficacious Therapy

8 R&D Strategies

8.1 Overview

8.1.1 Novel MOAs

8.1.2 Biomarkers

8.2 Clinical Trials Design

8.2.1 Patient inclusion criteria

8.2.2 Endpoints

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and barriers

12.5 Canada

12.5.1 Forecast

12.5.2 Key events

12.5.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Epidemiologist

13.6.4 Reviewers

13.6.5 Global Director of Therapy Analysis and Epidemiology

Table

Table 1: CD: Key metrics in the 8MM 7

Table 2: Crohn’s disease severities 20

Table 3: Risk factors and comorbidities for CD 22

Table 4: Treatment guidelines for CD 50

Table 5: Top 10 deals by value, 2011–2022 79

Table 6: CD market – global drivers and barriers, 2022–32 82

Table 7: Key events impacting sales for CD in the US, 2022–32 84

Table 8: CD market – drivers and barriers in the US, 2022–32 84

Table 9: Key events impacting sales for CD in the 5EU, 2022–32 87

Table 10: CD market – drivers and barriers in the 5EU, 2022–32 87

Table 11: Key events impacting sales for CD in Japan, 2022–32 90

Table 13: Key events impacting sales for CD in Canada, 2022–32 93

Table 14: CD market – drivers and barriers in Canada, 2022–32 93

Table 15: High-prescribing physicians (non-KOLs) surveyed, by country 108

Figures

Figure 1: Global sales forecast by country for CD in 2022 and 2032 8

Figure 2: Analysis of the company portfolio gap in CD during the forecast period 10

Figure 3: Competitive assessment of the late-stage biologics benchmarked against Humira 12

Figure 4: Competitive assessment of the late-stage small molecules benchmarked against Rinvoq 13

Figure 5: Pathophysiology of Crohn’s Disease 18

Figure 6: 8MM, diagnosed incidence of CD, men and women, cases per 100,000 population, all ages, 2022 23

Figure 7: 8MM, diagnosed prevalence of CD, men and women, %, all ages, 2022 24

Figure 8: 8MM, sources used and not used to forecast the diagnosed incident cases of CD 25

Figure 9: 8MM, sources used and not used to forecast the diagnosed prevalent cases of CD 26

Figure 10: 8MM, diagnosed incident cases of CD, N, both sexes, all ages, 2022 36

Figure 11: 8MM, diagnosed incident cases of CD by age, N, both sexes, 2022 37

Figure 12: 8MM, diagnosed incident cases of CD by sex, N, all ages, 2022 38

Figure 13: 8MM, diagnosed prevalent cases of CD, N, both sexes, all ages, 2022 39

Figure 14: 8MM, diagnosed prevalent cases of CD by age, N, both sexes, 2022 40

Figure 15: 8MM, diagnosed prevalent cases of CD by sex, N, all ages, 2022 41

Figure 16: 8MM, diagnosed prevalent cases of CD by severity, N, both sexes, ages <18 years, 2022 42

Figure 17: 8MM, diagnosed prevalent cases of CD by severity, N, both sexes, ages ≥18 years, 2022 43

Figure 18: 8MM, diagnosed prevalent cases of fistulizing CD by severity, N, both sexes, ages <18 years, 2022 44

Figure 19: 8MM, diagnosed prevalent cases of fistulizing CD by severity, N, both sexes, ages ≥18 years, 2022 44

Figure 20: 8MM, diagnosed prevalent cases of CD in remission by severity, N, both sexes, ages <18 years, 2022 45

Figure 21: 8MM, diagnosed prevalent cases of CD in remission by severity, N, both sexes, ages ≥18 years, 2022 46

Figure 22: Unmet needs and opportunities in CD 57

Figure 23: Overview of the development pipeline in CD 70

Figure 24: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for CD in the 8MM during the forecast period 72

Figure 25: Competitive assessment of the late-stage biologics benchmarked against Humira 75

Figure 26: Competitive assessment of the late-stage small molecules benchmarked against Rinvoq 76

Figure 27: Analysis of the company portfolio gap in CD during the forecast period 78

Figure 28: Global (8MM) sales forecast by country for CD in 2022 and 2032 81

Figure 29: Sales forecast by class for CD in the US in 2022 and 2032 83

Figure 30: Sales forecast by class for CD in the 5EU in 2022 and 2032 86

Figure 31: Sales forecast by class for CD in Japan in 2022 and 2032 89

Figure 32: Sales forecast by class for CD in Canada in 2022 and 2032 92

Frequently asked questions

Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 in real time.

  • Access a live Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.